American college of endocrinology pre-diabeles consensus conference: Part one

Diabetes Care

Volumn 31, Issue 10, 2008, Pages 2062-2069

  Bloomgarden, Zachary T ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; AMLODIPINE; BENAZEPRIL PLUS HYDROCHLOROTHIAZIDE; GLUCOSE; HEMOGLOBIN A1C; HYDROCHLOROTHIAZIDE PLUS LOSARTAN; METFORMIN; RAMIPRIL; ROSIGLITAZONE; TRANDOLAPRIL PLUS VERAPAMIL; TROGLITAZONE;

ARTICLE; AUTONOMIC NEUROPATHY; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CONSENSUS; DIABETES MELLITUS; DIABETIC NEUROPATHY; DISEASE ASSOCIATION; GLUCOSE BLOOD LEVEL; HUMAN; IMPAIRED GLUCOSE TOLERANCE; JUVENILE DIABETES MELLITUS; LIFESTYLE MODIFICATION; MEDICAL SOCIETY; METABOLIC SYNDROME X; ORAL GLUCOSE TOLERANCE TEST; RISK FACTOR; SCORING SYSTEM; BLOOD PRESSURE; CONFERENCE PAPER; DIABETIC ANGIOPATHY; FINLAND; PATHOPHYSIOLOGY; PREVALENCE; RISK ASSESSMENT; UNITED STATES;

BLOOD PRESSURE; DIABETES MELLITUS; DIABETIC ANGIOPATHIES; FINLAND; HUMANS; PREDIABETIC STATE; PREVALENCE; RISK ASSESSMENT; UNITED STATES;

EID: 56149124432     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc08-zb10     Document Type: Article

References (80)

1. Pepe MS, Janes H, Longton G, Leisenring W, Newcomb P: Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker. Am ] Epidemiol 159:882-890, 2004
2. Stern MP, Williams K, Haffner SM: Identification of persons at high risk for type 2 diabetes mellitus: do we need the oral glucose tolerance test? Ann Intern Med 136: 575-581, 2002
3. Wilson PW, DΆgostino RB, Levy D, Be-langer AM, Silbershatz H, Kannel WB: Prediction of coronary heart disease using risk factor categories. Circulation 97:1837-1847, 1998
4. Genuth S, Kahn R: A step backward-or is it forward? Diabetes Care 31:1093-1096, 2008
5. Saudek CD, Herman WH, Sacks DB, Ber-genstal RM, Edelman D, Davidson MB: A new look at screening and diagnosing diabetes mellitus. J Clin Endocrínol Metab 93: 2447-2453, 2008
6. Borch-Johnsen K, Colagiuri S, Balkau B, Glümer C, Carstensen B, Ramachandran A, Dong Y, Gao W: Creating a pandemic of prediabetes: the proposed new diagnostic criteria for impaired fasting glycae-mia. Ό iabetologia 47:1396-1402, 2004
7. Forouhi NG, Balkau B, Borch-Johnsen K, Dekker J, Glumer C, Qiao Q, Spijkerman A, Stolk R, Tabac A, Wareham NJ; EDEG. The threshold for diagnosing impaired fasting glucose: a position statement by the European Diabetes Epidemiology Group. Όiabetologia 49:822-827, 2006
8. de Vegt F, Dekker JM, Jager A, Hienkens E, Kostense PJ, Stehouwer CD, Nijpels G, Bouter LM, Heine RJ: Relation of impaired fasting and postload glucose with incident type 2 diabetes in a Dutch population: theHoornStudy. JAMA 285:2109-2113, 2001 9. Rijkelijkhuizen JM, Nijpels G, Heine RJ, Bouter LM, Stehouwer CD, Dekker JM: High risk of cardiovascular mortality in individuals with impaired fasting glucose is explained by conversion to diabetes: the Hoorn study. Diabetes Care 30:332-326, 2007
9. The DECODE Study Group, the European Diabetes Epidemiology Group: Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and noncardiovascular diseases? Diabetes Care 26:688-696, 2003
10. Pankow JS, Kwan DK, Duncan BB, Schmidt MI, Couper DJ, Golden S, Ballan-tyne CM: Cardiometabolic risk in impaired fasting glucose and impaired glucose tolerance: the Atherosclerosis Risk in Communities Study. Diabetes Care 30:325-331, 2007
11. YudkinJS, Forrest RD, Jackson CA, Ryle AJ, Davie S, Gould BJ: Unexplained variability of glycated haemoglobin in non-diabetic subjects not related to glycaemia. Diabetologia 33:208-215, 1990
12. Nathan DM, Kuenen J, Borg R, Zheng H, Schoenfeld D, Heine RJ, the Ale-Derived Average Glucose (ADAG) Study Group: Translating the A1C assay into estimated average glucose values. Diabetes Care 31: 1473-1478, 2008
13. lc in nondiabetic twins. Diabetes Care 29: 1739-1743, 2006
14. Bloomgarden ZT, Inzucchi SE, Karnieli E, Le Roith D: The proposed terminology Ά(lc)-derived average glucose' is inherently imprecise and should not be adopted. Όiabetologia 51:1111-1114, 2008
15. Ford ES: Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care 28:1769-1778,2005
16. Ferrannini E, Balkau B, Coppack SW, Dekker JM, Mari A, Nolan J, Walker M, Natali A, Beck-Nielsen H; RISC Investigators: Insulin resistance, insulin response, and obesity as indicators of metabolic risk. J Clin Endocrínol Metab 92:2885-2892, 2007
17. Hu FB, Stampfer MJ, Haffner SM, Solomon CG, Willett WC, Manson JE: Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes. Diabetes Care 25:1129-1134, 2002
18. Williams DE, Cadwell BL, Cheng YJ, Cowie CC, Gregg EW, Geiss LS, Engelgau MM, Narayan KM, Imperatore G: Prevalence of impaired fasting glucose and its relationship with cardiovascular diseaserisk factors in US adolescents, 1999-2000. Pediatrics 116:1122-1126, 2005
19. Bacha F, Saad R, Gungor N, Janosky J, Arslanian SA: Obesity, regional fat distribution, and syndrome X in obese black versus white adolescents: race differential in diabetogenic and atherogenic risk factors. ] Clín Endocrínol Metab 88:2534-2540, 2003
20. FernandezJR, Redden DT, Pietrobelli A, Allison DB: Waist circumference percentiles in nationally representative samples of African-American, European-American, and Mexican-American children and adolescents. J Pedíatr 145:439-444, 2004
21. Sun SS, Liang R, Huang TT, Daniels SR, Arslanian S, Liu K, Grave GD, Siervogel RM: Childhood obesity predicts adult metabolic syndrome: the Fels Longitudinal Study. J Pedíatr 152:191-200, 2008
22. Bacha F, Saad R, Gungor N, Arslanian SA: Are obesity-related metabolic risk factors modulated by the degree of insulin resistance in adolescents? Diabetes Care 29: 1599-1604, 2006
23. Arslanian SA, Lewy VD, Danadian K: Glucose intolerance in obese adolescents with polycystic ovary syndrome: roles of insulin resistance and beta-cell dysfunction and risk of cardiovascular disease. ] Clín Endocrínol Metab 86:66-71, 2001
24. Weiss R, Caprio S, Trombetta M, Taksali SE, Tamborlane WV, Bonadonna R: ß-Cell function across the spectrum of glucose tolerance in obese youth. Diabetes 54:1735-1743,2005
25. Cali AM, Bonadonna RC, Trombetta M, Weiss R, Caprio S: Metabolic abnormalities underlying the different prediabetic phenotypes in obese adolescents. ] Clín Endocrínol Metab 93:1767-1773, 2008
26. Gungor N, Bacha F, Saad R, Janosky J, Arslanian S: Youth type 2 diabetes: insulin resistance, ß-cell failure, or both? Diabetes Care 28:638-644, 2005
27. Berenson GS, Srinivasan SR, Bao W, Newman WP 3rd, Tracy RE, Wattigney WA: Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults: the Bogalusa Heart Study. N Engl ] Med 338:1650-1656, 1998
28. Gungor N, Thompson T, Sutton-Tyrrell K, Janosky J, Arslanian S: Early signs of cardiovascular disease in youth with obesity and type 2 diabetes. Diabetes Care 28: 1219-1221,2005
29. Lee S, Gungor N, Bacha F, Arslanian S: Insulin resistance: link to the components of the metabolic syndrome and biomark-ers of endothelial dysfunction in youth. Diabetes Care 30:2091-2097', 2007
30. Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD): Guidelines on diabetes, pre-dia-betes, and cardiovascular diseases: execu-tive summary. Eur Heart ] 28:88-136, 2007
31. The DECODE study group, the European Diabetes Epidemiology Group: Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe: glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Lancet 354:617-621, 1999
32. Nakagami T, the DECODA Study Group: Hyperglycaemia and mortality from all causes and from cardiovascular disease in ñve populations of Asian origin. Díabeto-logia 47: 385-394, 2004
33. Niskanen L, Turpeinen A, Penttilã I, Uus-itupa MI: Hyperglycemia and compositional lipoprotein abnormalities as predictors of cardiovascular mortality in type 2 diabetes: a 15-year follow-up from the time of diagnosis. Diabetes Care 21: 1861-1869, 1998
34. Bartnik M, Rydén L, Ferrari R, Malmberg K, Pyörälä K, Simoons M, Standl E, Soler-Soler J, Ohrvik J; Euro Heart Survey Investigators: The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe: the Euro Heart Survey on diabetes and the heart. Eur Heart ] 25:1880-1890, 2004
35. Hu DY, Pan CY, Yu JM; China Heart Survey Group: The relationship between coronary artery disease and abnormal glucose regulation in China: the China Heart Survey. Eur Heart] 27:2573-2579, 2006
36. Bartnik M, Rydén L, Malmberg K, Ohrvik J, Pyörälä K, Standl E, Ferrari R, Simoons M, Soler-Soler J; Euro Heart Survey Investigators: Oral glucose tolerance test is needed for appropriate classification of glucose regulation in patients with coronary artery disease: a report from the Euro Heart Survey on Diabetes and the Heart. Heart 93:72-77, 2007
37. Lenzen M, Ryden L, Ohrvik J, Bartnik M, Malmberg K, Scholte Op Reimer W, Simoons ML; Euro Heart Survey Investigators: Diabetes known or newly detected, but not impaired glucose regulation, has a negative influence on 1-year outcome in patients with coronary artery disease: a report from the Euro Heart Survey on diabetes and the heart. Eur Heart J 27: 2969-2974, 2006
38. Anselmino M, Ohrvik J, Malmberg K, Standl E, Rydén L; Euro Heart Survey Investigators. Glucose lowering treatment in patients with coronary artery disease is prognostically important not only in established but also in newly detected diabetes mellitus: a report from the Euro Heart Survey on Diabetes and the Heart. Eur Heart] 29:177-184, 2008
39. Anselmino M, Malmberg K, Ohrvik J, Rydén L, the Euro Heart Survey Investigators: Evidence-based medication and revascularization: powerful tools in the management of patients with diabetes andcoronary artery disease: a report from the Euro Heart Survey on diabetes and the heart. Eur J Cardíovasc Prev Rehabíl 15: 216-223,2008
40. Brohall G, Oden A, Fagerberg B: Carotid artery intima-media thickness in patients with type-2 diabetes mellitus and impaired glucose tolerance: a systematic review. Diabet Med 23:609-616, 2006
41. Matz K, Keresztes K, Tatschl C, Nowotny M, Dachenhausenm A, Brainin M, Tuom-ilehto J: Disorders of glucose metabolism in acute stroke patients. Diabetes Care 29: 792-797, 2006
42. Vermeer SE, Sandee W, Algra A, Koud-staal PJ, Kappelle LJ, Dippel DW: Impaired glucose tolerance increases stroke risk in nondiabetic patients with transient ischemic attack or minor ischemic stroke. Stroke 37:1413-1417, 2006
43. Lindström J, Tuomilehto J: The diabetes risk score: a practical tool to predict type 2 diabetes risk. Diabetes Care 26:725-731. 2003
44. Silventoinen K, Pankow J, Lindström J, Jousilahti P, Hu G, Tuomilehto J: The validity of the Finnish Diabetes Risk Score for the prediction of the incidence of coronary heart disease and stroke, and total mortality. Eur J Cardíovasc Prev Rehabil 12:451-458,2005
45. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM; Diabetes Prevention Program Research Group: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl ] Med 346:393-403, 2002
46. Tuomilehto J, Lindström J, Eriksson JG, Valle TT, Hämäläinen H, Ilanne-Parikka P, Keinänen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, Salminen V, Uusitupa M; Finnish Diabetes Prevention Study Group: Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344:1343-1350, 2001
47. Lindström J, llanne-Parikka P, Peltonen M, Aunola S, Eriksson JG, Hemiö K, Hämäläinen H, Härkönen P, Keinänen-Kiukaanniemi S, Laakso M, Louheranta A, Mannelin M, Paturi M, Sundvall J, Valle TT, Uusitupa M, Tuomilehto J; Finnish Diabetes Prevention Study Group: Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet 368:1673-1679, 2006
48. Li G, Zhang P, Wang J, Gregg EW, Yang W, Gong Q, Li H, Li H, Jiang Y, An Y, Shuai Y, Zhang B, Zhang J, Thompson TJ, Gerzoff RB, Roglic G, Hu Y, Bennett PH: The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study. Lancet 371:1783-1789, 2008
49. Diabetes Prevention Program ResearchGroup: The prevalence of retinopathy in impaired glucose tolerance and recent-onset diabetes in the Diabetes Prevention Program. Diabet Med 24:137-144, 2007
50. DREAM Trial Investigators: Effects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial. Diabetes Care 31:1007-1014, 2008
51. Ratner R, Goldberg R, Haffner S, Marcovina S, Orchard T, Fowler S, Temprosa M, the Diabetes Prevention Program Research Group: Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the diabetes prevention program. Diabetes Care 28:888-894, 2005
52. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M; STOP-NIDDM Trail Research Group: Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 359:2072-2077, 2002
53. Orchard TJ, Temprosa M, Goldberg R, Haffner S, Ratner R, Marcovina S, Fowler S; Diabetes Prevention Program Research Group: The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial. Ann Intern Med 142:611-619,2005
54. Haffner S, Temprosa M, Crandall J, Fowler S, Goldberg R, Horton E, Marcovina S, Mather K, Orchard T, Ratner R, Barrett-Connor E, the Diabetes Prevention Program Research Group: Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes 54:1566-1572, 2005
55. Xiang AH, Peters RK, Kjos SL, Ochoa C, Marroquin A, Goico J, Tan S, Wang C, Azen SP, Liu CR, Liu CH, Hodis HN, Buchanan TA: Effect of thiazolidinedione treatment on progression of subclinical atherosclerosis in premenopausal women at high risk for type 2 diabetes. J Clín En-docrínol Metab 90:1986-1091, 2005
56. Hanefeld M, Chiasson JL, Koehler C, Henkel E, Schaper F, Temelkova-Kurktschiev T: Acarbose slows progression of intima-media thickness of the carotid arteries in subjects with impaired glucose tolerance. Stroke 35:1073-1078. 2004
57. Herman WH, Hoerger TJ, Brandle M, Hicks K, Sorensen S, Zhang P, Hamman RF, Ackermann RT, Engelgau MM, Ratner RE; Diabetes Prevention Program Research Group: The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Ann Intern Med 142:323-332, 2005
58. Borch-Johnsen K, Feldt-Rasmussen B, Strandgaard S, Schroll M, Jensen JS: Urinary albumin excretion: an independent predictor of ischemic heart disease. Arterioscler Thromb Vase Bid 19:1992-1997, 1999
59. Kistorp C, Raymond I, Pedersen F, Gustafsson F, Faber J, Hildebrandt P: N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults JAMA 293:1609-1616,2005
60. So WY, Kong AP, Ma RC, Ozaki R, Szeto CC, Chan NN, Ng V, Ho CS, Lam CW, Chow CC, Cockram CS, ChanJC, Tong PC: Glomerular filtration rate, cardiorenal end points, and all-cause mortality in type 2 diabetic patients. Diabetes Care 29: 2046-2052, 2006
61. Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, Van Lente F, Levey AS: Prevalence of chronic kidney disease in the United States. JAMA 298:2038-2047, 2007
62. Bakris GL, Williams M, Dworkin L, Elliott WJ, Epstein M, Toto R, Tuttle K, Douglas J, Hsueh W, Sowers J, the National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group: Preserving renal function in adults with hypertension and diabetes: a consensus approach. Am] Kidney Dis 36: 646-661, 2000
63. 63a.Ong KL, Cheung BM, Man YB, Lau CP, Lam KS: Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004. Hypertension 40:69-75, 2007
64. Peralta CA, Hicks LS, Chertow GM, Aya-nian JZ, Vittinghoff E, Lin F, Shlipak MG: Control of hypertension in adults with chronic kidney disease in the United States: Hyperfensíon45:1119-1124, 2005
65. Heeg JE, de Jong PE, van der Hem GK, de Zeeuw D: Efficacy and variability of the an-tiproteinuric effect of ACE inhibition by lis-inopril. Kidney lnt 36:272-279, 1989
66. Buter H, Hemmelder MH, Navis G, de Jong PE, de Zeeuw D: The blunting of the antiproteinuric efficacy of ACE inhibition by high sodium intake can be restored by hydrochlorothiazide. Nephrol Dial Transplant 13:1682-1685, 1998
67. Appel LJ, Moore TJ, Obarzanek E, Vollmer WM, Svetkey LP, Sacks FM, Bray GA, Vogt TM, Cutler JA, Windhauser MM, Lin PH, Karanja N, the DASH Collaborative Research Group: A clinical trial of the effects of dietary patterns on blood pressure. N Engl J Med 336:1117-1124, 1997
68. Bakris G, Molitch M, Hewkin A, Kipnes M, Sarafìdis P, Fakouhi K, Bacher P, Sowers J, the STAR Investigators: Differences in glucose tolerance between fixed-dose antihypertensive drug combinations inpeople with metabolic syndrome. Diabetes Care 29:2592-2597, 2006
69. Jamerson KA, Bakris GL, Wun CC, Dahlöf B, Lefkowitz M, Manfreda S, Pitt B, Velazquez EJ, Weber MA: Rationale and design of the avoiding cardiovascular events through combination therapy in patients living with systolic hypertension (ACCOMPLISH) trial: the first randomized controlled trial to compare the clinical outcome effects of first-line combination therapies in hypertension. Am] Hypertens 17:793-801, 2004
70. Sumner CJ, Sheth S, Griffin JW, Cornblath DR, Polydefkis M: The spectrum of neuropathy in diabetes and impaired glucose tolerance. Neurology 60:108-111, 2003
71. Pittenger GL, Mehrabyan A, Simmons K, Amandarice, Dublin C, Barlow P, Vinik AI: Small fiber neuropathy is associated with the metabolic syndrome. Metab Syndr Relat Disord 3:113-121, 2005
72. Singleton JR, Smith AG, Russell JW, Feld-man EL: Microvascular complications of impaired glucose tolerance. Diabetes 52: 2867-2873, 2003
73. Novella SP, Inzucchi SE, Goldstein JM: The frequency of undiagnosed diabetes and impaired glucose tolerance in patients with idiopathic sensory neuropathy. Muscle Nerve 24:1229-1231, 2001
74. WuJS, YangYC, LinTS, Huang YH, Chen JJ, Lu FH, Wu CH, Chang CJ: Epidemio-logical evidence of altered cardiac auto-nomic function in subjects with impaired glucose tolerance but not isolated impaired fasting glucose. J Clín Endocrinol Metab 92:3885-3889, 2007
75. Carnethon MR, Prineas RJ, Temprosa M, Zhang ZM, Uwaifo G, Molitch ME, the Diabetes Prevention Program Research Group: The association among autonomic nervous system function, incident diabetes, and intervention arm in the Diabetes Prevention Program. Diabetes Care 29: 914-919,2006
76. Vinik AI, Maser RE, Mitchell BD, Freeman R: Diabetic autonomic neuropathy. Diabetes Care 26:1553-1579, 2003
77. Pittenger GL, Ray M, Burcus NI, McNulty P, Basta B, Vinik AI: Intraepidermal nerve fibers are indicators of small-fiber neuropathy in both diabetic and nondiabetic patients. Diabetes Care 27:1974-1979, 2004
78. Vinik AI, Ziegler D: Diabetic cardiovascular autonomic neuropathy. Circulation 115:387-397,2007
79. Smith AG, SingletonJR: Impaired glucose tolerance and neuropathy. Neurologist 14: 23-29, 2008
80. Curb JD, Rodriguez BL, Burchfìel CM, Abbott RD, Chiu D, Yano K: Sudden death, impaired glucose tolerance, and diabetes in Japanese American men. Circulation 91:2591-2595, 1995